JP3757986B2 - 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 - Google Patents

上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 Download PDF

Info

Publication number
JP3757986B2
JP3757986B2 JP54839998A JP54839998A JP3757986B2 JP 3757986 B2 JP3757986 B2 JP 3757986B2 JP 54839998 A JP54839998 A JP 54839998A JP 54839998 A JP54839998 A JP 54839998A JP 3757986 B2 JP3757986 B2 JP 3757986B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
human
egf
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54839998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523973A (ja
JP2001523973A5 (enExample
Inventor
アヤ ジャコボビッツ
クシャオ−ドン ヤン
マイケル ギャロ
クシャオ−チ ジア
Original Assignee
アブジェニックス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブジェニックス インク． filed Critical アブジェニックス インク．
Publication of JP2001523973A publication Critical patent/JP2001523973A/ja
Publication of JP2001523973A5 publication Critical patent/JP2001523973A5/ja
Application granted granted Critical
Publication of JP3757986B2 publication Critical patent/JP3757986B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP54839998A 1997-05-05 1998-05-05 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 Expired - Lifetime JP3757986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/851,362 US6235883B1 (en) 1997-05-05 1997-05-05 Human monoclonal antibodies to epidermal growth factor receptor
US08/851,362 1997-05-05
PCT/US1998/009160 WO1998050433A2 (en) 1997-05-05 1998-05-05 Human monoclonal antibodies to epidermal growth factor receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005050969A Division JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2001523973A JP2001523973A (ja) 2001-11-27
JP2001523973A5 JP2001523973A5 (enExample) 2005-09-08
JP3757986B2 true JP3757986B2 (ja) 2006-03-22

Family

ID=25310591

Family Applications (9)

Application Number Title Priority Date Filing Date
JP54839998A Expired - Lifetime JP3757986B2 (ja) 1997-05-05 1998-05-05 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2005050969A Withdrawn JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008147230A Withdrawn JP2008273986A (ja) 1997-05-05 2008-06-04 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008276447A Withdrawn JP2009051861A (ja) 1997-05-05 2008-10-28 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2010052859A Expired - Lifetime JP5356287B2 (ja) 1997-05-05 2010-03-10 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2012104486A Withdrawn JP2012158601A (ja) 1997-05-05 2012-05-01 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2014122089A Withdrawn JP2014185165A (ja) 1997-05-05 2014-06-13 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2016149288A Withdrawn JP2017025064A (ja) 1997-05-05 2016-07-29 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2017224446A Withdrawn JP2018076321A (ja) 1997-05-05 2017-11-22 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2005050969A Withdrawn JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008147230A Withdrawn JP2008273986A (ja) 1997-05-05 2008-06-04 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008276447A Withdrawn JP2009051861A (ja) 1997-05-05 2008-10-28 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2010052859A Expired - Lifetime JP5356287B2 (ja) 1997-05-05 2010-03-10 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2012104486A Withdrawn JP2012158601A (ja) 1997-05-05 2012-05-01 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2014122089A Withdrawn JP2014185165A (ja) 1997-05-05 2014-06-13 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2016149288A Withdrawn JP2017025064A (ja) 1997-05-05 2016-07-29 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2017224446A Withdrawn JP2018076321A (ja) 1997-05-05 2017-11-22 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Country Status (16)

Country Link
US (1) US6235883B1 (enExample)
EP (3) EP1878746A3 (enExample)
JP (9) JP3757986B2 (enExample)
KR (1) KR100558110B1 (enExample)
AT (1) ATE366747T1 (enExample)
AU (1) AU7287098A (enExample)
CA (1) CA2288962C (enExample)
CY (2) CY1107708T1 (enExample)
DE (2) DE122008000009I1 (enExample)
DK (1) DK0979246T3 (enExample)
ES (1) ES2289779T3 (enExample)
FR (1) FR08C0006I2 (enExample)
LU (1) LU91411I2 (enExample)
NL (1) NL300335I2 (enExample)
PT (1) PT979246E (enExample)
WO (1) WO1998050433A2 (enExample)

Families Citing this family (1092)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219361C (en) * 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US20050287630A1 (en) * 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20050241006A1 (en) * 1995-04-27 2005-10-27 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7491530B2 (en) * 2001-12-18 2009-02-17 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
WO2004043405A2 (en) * 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
AU2003300899A1 (en) * 2002-12-12 2004-06-30 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
WO2004092220A1 (en) * 2003-04-14 2004-10-28 Board Of Regents, The University Of Texas System Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20070036795A1 (en) 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
MXPA05014155A (es) * 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2128270B1 (en) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis biomarkers and uses thereof
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
EP1759010A4 (en) * 2004-01-07 2008-12-24 Bristol Myers Squibb Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
EP2369014A1 (en) 2004-02-03 2011-09-28 The Regents Of The University Of Michigan Office Of Technology Transfer Compositions and methods for characterizing, regulating, diagnosing and treating cancer
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
US7625549B2 (en) * 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
KR100680141B1 (ko) * 2005-04-20 2007-02-07 주식회사 녹십자 항-ｅｇｆ 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
EP1959979A4 (en) 2005-11-04 2010-01-27 Biogen Idec Inc PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗ｅｇｆｒ抗体
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
KR20090058512A (ko) 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
EP2061906B1 (en) 2006-09-12 2011-08-31 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008079973A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
WO2008079982A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Liposome composition for targeting egfr receptor
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
JP2010513321A (ja) * 2006-12-22 2010-04-30 ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
KR20080074683A (ko) * 2007-02-09 2008-08-13 삼성전자주식회사 디지털 저작권 관리 방법 및 장치
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US20080293055A1 (en) 2007-03-13 2008-11-27 Daniel Freeman K-ras mutations and anti-EGFr antibody therapy
PL2412828T3 (pl) 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
PT3072525T (pt) 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009054917A1 (en) 2007-10-19 2009-04-30 Amgen Inc. Methods of selecting epidermal growth factor receptor (egfr) binding agents
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
AU2009221120A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
JP5593220B2 (ja) 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
KR20110040886A (ko) 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
MX2011001927A (es) * 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
US20120288495A1 (en) 2009-07-22 2012-11-15 Biothera, Inc. Therapeutic compositions and methods
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
CA2800230A1 (en) 2010-03-04 2011-09-09 Hospital District Of Southwest Finland Method for selecting patients for treatment with an egfr inhibitor
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
EP2371369A1 (en) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
WO2011130417A2 (en) * 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
KR20130058672A (ko) 2010-04-16 2013-06-04 제넨테크, 인크. ＰＩ3Ｋ/ＡＫＴ 키나제 경로 억제제 효능에 대한 예측 바이오마커로서의 ＦＯＸＯ３ａ
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012019160A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
EP2640738A1 (en) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
GB201106870D0 (en) 2011-04-26 2011-06-01 Univ Belfast Marker
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
AU2012274156A1 (en) 2011-06-20 2014-01-23 Traslational Cancer Drugs Pharma, S.L. Method for predicting the clinical response to chemotherapy in a subject with cancer
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
SI2726600T1 (sl) 2011-07-01 2017-07-31 Amgen Inc. Sesalska celična kultura
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
RU2014105624A (ru) 2011-08-12 2015-09-20 Ф. Хоффманн-Ля Рош Аг Соединения индазола, способ их применения и фармацевтическая композиция
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013033600A1 (en) 2011-09-02 2013-03-07 Amgen Inc. Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
MX351251B (es) 2011-09-09 2017-10-06 Amgen Inc Uso del estado del virus del papiloma humano en establecer el uso de un agente que enlaza el receptor del factor de crecimiento anti-epidermal en el tratamiento de cáncer.
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
BR112014006643A2 (pt) 2011-09-20 2017-04-04 Hoffmann La Roche compostos de imidazopiridina, composições e métodos de uso dos mesmos
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
DK2766392T3 (da) 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
JP2014533954A (ja) 2011-11-21 2014-12-18 イミュノジェン， インコーポレイテッド Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CN103172741B (zh) * 2011-12-20 2018-04-27 智翔（上海）医药科技有限公司 全人源抗egfr抗体
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
CN104471064B (zh) 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013120012A2 (en) * 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center TIKI INHIBITORS
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
JP6441792B2 (ja) * 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2874407A1 (en) 2012-05-24 2013-11-28 Fundacio Institut D'investigacio Biomedica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
IN2015DN00450A (enExample) 2012-08-07 2015-06-26 Novartis Ag
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
NO2760138T3 (enExample) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
WO2014063205A1 (en) 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
TW201838651A (zh) 2012-11-01 2018-11-01 美商艾伯維有限公司 穩定雙重可變區域免疫球蛋白蛋白質調配物
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
US9994908B2 (en) 2013-03-14 2018-06-12 Abbott Molecular Inc. Materials and methods for assessment of colorectal adenoma
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
BR112015025549A2 (pt) * 2013-04-07 2017-10-10 Bioex Therapeutics Inc anticorpo contra o receptor do fator de crescimento epidérmico
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2016518361A (ja) 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
CN103290018B (zh) * 2013-05-07 2015-07-29 南方医科大学 一种与人表皮生长因子受体iii型突变体特异性结合的核酸适配子及其应用
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2015000062A1 (en) 2013-07-05 2015-01-08 Avidbiologics Inc. Egfr antibody conjugates
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
KR20160049003A (ko) 2013-09-05 2016-05-04 제넨테크, 인크. 항증식성 화합물
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
EP3733868A3 (en) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergen detection
SI3063287T1 (sl) 2013-10-31 2025-06-30 Amgen, Inc. Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016011222A2 (pt) 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
WO2015088346A1 (en) 2013-12-13 2015-06-18 Rijksuniversiteit Groningen Antibodies against staphylococcus aureus and uses thereof.
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
CN106170554B (zh) 2014-01-29 2021-08-17 美国安进公司 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
JP6792454B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
MA40539A (fr) 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN107073125A (zh) 2014-09-19 2017-08-18 基因泰克公司 Cbp/ep300和bet抑制剂用于治疗癌症的用途
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
US20170252335A1 (en) 2014-10-17 2017-09-07 Novartis Ag Combination of Ceritinib with an EGFR Inhibitor
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3217989B1 (en) 2014-10-31 2022-01-05 The Trustees of the University of Pennsylvania Compositions and methods of stimulating and expanding t cells
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
CA2966507A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CA2963974A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
ES2962593T3 (es) 2014-11-19 2024-03-20 Amgen Inc Cuantificación de resto glucano en glucoproteínas recombinantes
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
EP3229844B1 (en) 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
ES2870983T3 (es) 2014-12-19 2021-10-28 Univ Nantes Anticuerpos anti-IL-34
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3237639A2 (en) 2014-12-23 2017-11-01 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
EP3240908A2 (en) 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3242875B1 (en) 2015-01-09 2022-02-23 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
AU2016313263B2 (en) 2015-08-26 2021-02-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
HRP20220227T1 (hr) 2015-12-16 2022-04-29 Genentech, Inc. Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
ES3011729T3 (en) 2015-12-31 2025-04-08 Ecs Progastrin Sa Compositions and methods for detecting and treating gastric cancer
BR112018013272A2 (en) 2015-12-31 2018-12-11 Progastrine Et Cancers S.À R.L. compositions and methods for detecting and treating esophageal cancer
CN108780091A (zh) 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
KR102620651B1 (ko) 2015-12-31 2024-01-04 신케레스 에스.에이 알.엘. 암 발생의 위험도를 평가하기 위한 조성물 및 방법
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
PT3219726T (pt) 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
IL261793B2 (en) 2016-03-17 2025-04-01 Numab Therapeutics AG ANTI-TNFALPHA ANTIBODIES AND THEIR FUNCTIONAL PARTS
EP3219727B1 (en) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
WO2017205536A2 (en) 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
SMT202100721T1 (it) 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
CN109312407A (zh) 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
KR102644544B1 (ko) 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
EP3519049B1 (en) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535294B1 (en) 2016-11-07 2025-02-12 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
UY37523A (es) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
JP7275030B2 (ja) 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体およびその使用
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
SG11201908998XA (en) 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CN110678753B (zh) 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 用于治疗肺癌的组合物和方法
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US12569497B2 (en) 2017-04-27 2026-03-10 The University Of Hong Kong Use of HCN inhibitors for treatment of cancer
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
AU2018304458B2 (en) 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
SG11202000634UA (en) 2017-07-27 2020-02-27 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
JP7795860B2 (ja) 2017-09-07 2026-01-08 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
KR20240017986A (ko) 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
CA3019207A1 (en) 2017-09-28 2019-03-28 The Governing Council Of The University Of Toronto Methods and compositions for inhibiting mutant egfr signaling
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019084395A1 (en) 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
DK3720879T3 (da) 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
US12174193B2 (en) 2018-01-15 2024-12-24 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
US20210363590A1 (en) 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
TWI890148B (zh) 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
US10976561B2 (en) 2018-06-29 2021-04-13 Viavi Solutions Inc. Optical devices with azimuthal modulator layer
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
EP3823991A4 (en) 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
EP3863672A4 (en) 2018-10-11 2022-06-29 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
EP3867405A4 (en) 2018-10-17 2022-07-20 The University of Queensland EPIGENETIC BIOMARKER AND USES THEREOF
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US12129305B2 (en) 2018-10-25 2024-10-29 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
EP3873912B1 (en) 2018-10-31 2026-03-25 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020127374A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
EP3898681A2 (en) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113330033B (zh) 2018-12-26 2024-11-29 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
KR102991359B1 (ko) 2018-12-28 2026-07-16 쿄와 기린 가부시키가이샤 TfR에 결합하는 이중 특이적 항체
MX2021004504A (es) 2019-01-02 2021-10-01 Neuracle Science Co Ltd Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
US20220153827A1 (en) 2019-01-15 2022-05-19 Janssen Biotech, Inc. Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
AU2019427766A1 (en) 2019-01-30 2021-09-16 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
CA3131036A1 (en) 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
SG11202108707WA (en) 2019-02-27 2021-09-29 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
KR102930430B1 (ko) 2019-03-15 2026-02-26 카티전 테라퓨틱스, 인코포레이티드 항-bcma 키메라 항원 수용체
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
TW202042824A (zh) 2019-03-27 2020-12-01 賓夕法尼亞大學董事會 Tn-MUC1嵌合抗原受體（CAR）T細胞療法
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
WO2020219719A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
MX2021013222A (es) 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
EP3983410A1 (en) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CN114450027A (zh) 2019-08-16 2022-05-06 儿童医院医疗中心 用cdc42特异性抑制剂治疗受试者的方法
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
CN117683133A (zh) 2019-09-03 2024-03-12 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
TW202519557A (zh) 2019-09-04 2025-05-16 美商建南德克公司 Cd8 結合劑及其用途
KR20220088428A (ko) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
EP4045515A4 (en) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan BIOMATERIAL SENSOR SYSTEMS
CN115003328A (zh) 2019-10-22 2022-09-02 西奈山伊坎医学院 重组神经氨酸酶及其用途
CN114728936A (zh) 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
JP7777524B2 (ja) 2019-11-04 2025-11-28 コード バイオセラピューティクス インコーポレイテッド 脳特異的血管新生抑制因子１（ｂａｉ１）抗体及びその使用
IL292458A (en) 2019-11-06 2022-06-01 Genentech Inc Diagnostic and treatment methods for the treatment of hematological cancer
EP4058435A1 (en) 2019-11-13 2022-09-21 Genentech, Inc. Therapeutic compounds and methods of use
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
CA3164995A1 (en) 2019-12-20 2021-06-24 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
TWI777364B (zh) 2020-01-15 2022-09-11 大陸商上海藥明生物技術有限公司 連續收穫由培養的細胞生產的生物物質的設備和方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US12678512B2 (en) 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
JP7859981B2 (ja) 2020-03-06 2026-05-15 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
WO2021197340A1 (zh) 2020-03-31 2021-10-07 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
JP2023524669A (ja) 2020-04-26 2023-06-13 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 改変免疫グロブリン
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
EP4185322A2 (en) 2020-07-24 2023-05-31 Amgen Inc. Immunogens derived from sars-cov2 spike protein
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
JP7904195B2 (ja) 2020-08-03 2026-08-12 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
TWI883241B (zh) 2020-08-07 2025-05-11 大陸商百奧泰生物製藥股份有限公司 抗pd-l1抗體及其應用
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP4210832A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
TW202446417A (zh) 2020-10-05 2024-12-01 美商建南德克公司 用抗 fcrh5/抗 cd3 雙特異性抗體進行治療之給藥
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022095970A1 (zh) 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 双特异抗体及其应用
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
EP4253415A4 (en) 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
WO2022104697A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity
AU2021381419A1 (en) * 2020-11-20 2023-06-29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity, drug conjugate, and use thereof
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20240101677A1 (en) 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
MX2023009379A (es) 2021-02-12 2023-10-10 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
BR112023018353A2 (pt) 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
JP7721635B2 (ja) 2021-03-12 2025-08-12 第一三共株式会社 糖鎖及び糖鎖を含む医薬品の製造方法
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
CA3221390A1 (en) 2021-05-25 2022-12-01 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
US20240352481A1 (en) 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
EP4384522A1 (en) 2021-08-10 2024-06-19 Erasca, Inc. Selective kras inhibitors
JP2024532167A (ja) 2021-08-16 2024-09-05 ヒーモジェニックス ファーマシューティカルズ エルエルシー 抗ｆｌｔ３抗体、ｃａｒ、ｃａｒ ｔ細胞、及び使用方法
US20240368288A1 (en) 2021-08-17 2024-11-07 Hemogenyx Pharmaceuticals Llc Bispecific anti-flt3/cd3 antibodies and methods of use
US12467921B2 (en) 2021-08-31 2025-11-11 Versitech Limited Antibodies and assays for detection of Burkholderia mallei
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｌａｍｐ１抗体およびその使用
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4410839A4 (en) 2021-09-30 2025-10-08 Bio Thera Solutions Ltd ANTI-B7-H3 ANTIBODY AND ITS USE
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
JP2024544555A (ja) 2021-11-15 2024-12-03 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病を処置する方法
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
US12110276B2 (en) 2021-11-24 2024-10-08 Genentech, Inc. Pyrazolo compounds and methods of use thereof
US12275745B2 (en) 2021-11-24 2025-04-15 Genentech, Inc. Therapeutic compounds and methods of use
WO2023102476A1 (en) 2021-12-02 2023-06-08 California Institute Of Technology Antibodies for coronaviruses and uses thereof
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
US20250144042A1 (en) 2022-02-22 2025-05-08 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
CA3246346A1 (en) 2022-03-29 2023-10-05 Netris Pharma NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20230144961A (ko) 2022-04-07 2023-10-17 트윈피그바이오랩(주) Itgb2 매개 약물전달체
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
JP2025517650A (ja) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
EP4526342A1 (en) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
EP4543494A1 (en) 2022-06-27 2025-04-30 Sutro Biopharma, Inc. Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
CN119585308A (zh) 2022-07-13 2025-03-07 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
JP2025523049A (ja) 2022-07-14 2025-07-17 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びその使用
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
CN119948030A (zh) 2022-07-15 2025-05-06 苏特罗生物制药公司 蛋白酶/酶可切割连接体-有效载荷及蛋白质偶联物
KR20250040020A (ko) 2022-07-19 2025-03-21 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
US20260035364A1 (en) 2022-08-11 2026-02-05 Hoffmann-La Roche Inc. Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
CN119677733A (zh) 2022-08-11 2025-03-21 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
KR20250064682A (ko) 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024085242A2 (en) 2022-10-21 2024-04-25 Kawasaki Institute Of Industrial Promotion Non-fouling or super stealth vesicle
JP2026500084A (ja) 2022-10-25 2026-01-06 ジェネンテック， インコーポレイテッド 多発性骨髄腫の治療方法および診断方法
KR20240066490A (ko) 2022-10-28 2024-05-16 주식회사 휴온스랩 항체-사이토카인 융합단백질 및 이의 용도
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
US20260217861A1 (en) 2022-12-22 2026-07-30 Jjulius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
EP4406973A1 (en) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
TW202448960A (zh) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
WO2024173842A1 (en) 2023-02-17 2024-08-22 Erasca, Inc. Kras inhibitors
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
EP4680344A1 (en) 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
AU2024315750A1 (en) 2023-07-31 2026-03-05 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025049272A1 (en) 2023-08-25 2025-03-06 The Broad Institute, Inc. Card9 variant polypeptide and antibodies directed thereto
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
EP4791439A1 (en) 2023-10-13 2026-08-19 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
JPWO2025105486A1 (enExample) 2023-11-17 2025-05-22
CN120118196A (zh) 2023-12-08 2025-06-10 百奥泰生物制药股份有限公司 融合蛋白及其应用
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
AU2024403128A1 (en) 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2025264647A1 (en) 2024-06-18 2025-12-26 Sutro Biopharma, Inc. Oxoadenine tlr7 agonist compounds and conjugates
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody
WO2026030476A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
FR3167160A1 (fr) 2024-10-08 2026-04-10 Alga Biologics Immunoglobulines avec affinite augmentee pour le fcrn
WO2026080697A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
WO2026080692A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Branched beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2026080688A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Dual mechanism of action payload antibody drug conjugates
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content
WO2026097015A1 (en) 2024-11-01 2026-05-07 Eindura Therapeutics, Inc. Targeted therapeutics with an electrophilic group for covalent attachment and methods of use and manufacture thereof
WO2026102349A1 (en) 2024-11-08 2026-05-15 Genentech, Inc. Anti-interleukin-23 receptor vhh antibodies and uses thereof
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EP1972194A1 (en) * 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
DE69838062T2 (de) 2008-01-31
DE69838062D1 (de) 2007-08-23
KR100558110B1 (ko) 2006-03-10
WO1998050433A2 (en) 1998-11-12
EP0979246A2 (en) 2000-02-16
FR08C0006I2 (fr) 2009-01-15
JP2001523973A (ja) 2001-11-27
JP2012158601A (ja) 2012-08-23
JP2009051861A (ja) 2009-03-12
JP2017025064A (ja) 2017-02-02
FR08C0006I1 (fr) 2008-08-21
JP2008273986A (ja) 2008-11-13
AU7287098A (en) 1998-11-27
JP2010150279A (ja) 2010-07-08
NL300335I2 (nl) 2008-06-02
PT979246E (pt) 2007-08-16
KR20010012243A (ko) 2001-02-15
US6235883B1 (en) 2001-05-22
HK1027114A1 (en) 2001-01-05
DK0979246T3 (da) 2007-11-05
ES2289779T3 (es) 2008-02-01
CY2008003I1 (el) 2009-11-04
LU91411I2 (fr) 2008-03-25
EP1878746A2 (en) 2008-01-16
CY1107708T1 (el) 2010-07-28
JP5356287B2 (ja) 2013-12-04
EP1878746A3 (en) 2011-05-25
EP2332993A1 (en) 2011-06-15
CY2008003I2 (el) 2009-11-04
CA2288962C (en) 2011-08-30
CA2288962A1 (en) 1998-11-12
WO1998050433A3 (en) 1999-02-04
DE122008000009I1 (de) 2008-04-30
JP2005225884A (ja) 2005-08-25
NL300335I1 (nl) 2008-04-01
EP0979246B1 (en) 2007-07-11
JP2018076321A (ja) 2018-05-17
JP2014185165A (ja) 2014-10-02
ATE366747T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
JP5356287B2 (ja) 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
US7807798B2 (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2003243139B2 (en) Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU777918B2 (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2004231235B2 (en) Human Monoclonal Antibodies to Epidermal Growth Factor Receptor
HK1157799A (en) Human monoclonal antibody to the human epidermal growth factor receptor
HK1027114B (en) Human monoclonal antibodies to epidermal growth factor receptor
HK1118833A (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2011265413B2 (en) Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
HK1157211A (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050112

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050112

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051220

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 3757986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100113

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term